Background:  RASSF8 (Ras association (RalGDS/AF-6 or RA) domain (N-terminal) family member 8), also known as HoJ-1 (carcinoma-associated protein HoJ-1), is an evolutionarily conserved member of the N-terminal RASSF family which is also comprised of RASSF7, PAMCI (or RASSF9) and RASSF10. RASSF8 contains an N-terminal RA domain and is believed to participate in the Ras signaling pathway. A reciprocal chromosomal translocation involving the genes encoding RASSF8 and Fibulin-1 is associated with a complex form of synpolydactyly, a condition in which there are typically more than five digits on a hand or foot and patients exhibit webbing or fusion of fingers and toes. In addition, RASSF8 is capable of acting as a tumor suppressor in lung cancer, as is suggested by the ectopic expression of RASSF8 inhibiting anchorage-independent growth. This implies that the loss of functional RASSF8 may be implicated in the development of lung cancer.

Description: Rabbit polyclonal to RASSF8

Immunogen: KLH conjugated synthetic peptide derived from RASSF8

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 45 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;

·Immunocytochemistry/Immunofluorescence: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.